EGFR and neoplasm: Mechanisms of acquired resistance are also frequently RAS-driven: under the selective pressure of anti-EGFR therapy, subclonal RAS mutations or gene amplifications can arise (detectable in tissue or circulating tumor DNA–ctDNA–), producing secondary resistance even in tumors that were RAS wild-type at baseline.